Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of December 2025, with the specific transaction date being December 1, 2025. The filing was submitted on December 2, 2025.
Key Financial Metrics
The filing details a share repurchase transaction executed through BNP Paribas SA. Key metrics for the transaction are as follows:
- Shares Purchased: 203,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,786.00p; highest price paid was 1,810.00p.
- Volume-Weighted Average Price (VWAP): 1,800.44p.
- Treasury Shares Held: Following this purchase, GSK holds 236,811,577 ordinary shares in treasury.
- Shares in Issue: 4,078,622,107 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 5.81% of the total voting rights.
Material Changes
This transaction is part of an existing buyback programme initiated under a non-discretionary agreement announced on September 30, 2025. Since the commencement of this agreement, GSK has purchased a total of 11,346,733 ordinary shares. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period, as it is a disclosure of a specific capital transaction rather than a financial results report.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and its Q3 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of treasury shares held (236,811,577) against the company's latest capital structure disclosures.
- Confirm the percentage of voting rights held in treasury (5.81%) to assess potential dilution or control implications.
- Review the remaining capacity under the buyback programme announced on September 30, 2025.
- Check the total number of shares in issue (4,078,622,107) for accurate EPS calculations.